A peptide that acts on nervous system pathways involved in sexual desire and response, not on blood flow. Here's what to know about its FDA status, and who it isn't for.
$199 / month(includes provider review, medication and shipping)
PT-141, also known as bremelanotide, is a synthetic peptide that acts on melanocortin receptors in the body, including receptors involved in pathways associated with sexual desire and arousal.
Unlike medications that primarily work by increasing blood flow, PT-141 acts on signaling pathways in the nervous system that are involved in sexual motivation and response. This makes it different from medications such as sildenafil (Viagra), which work primarily by improving blood flow to support erections.
Bremelanotide is the active ingredient in Vyleesi®, an FDA-approved prescription medication for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in certain premenopausal women.
It is important to understand that FDA approval of Vyleesi® applies to its specific formulation and approved indication. It does not mean that all compounded PT-141 products, formulations, or uses are FDA-approved.
Bremelanotide is the active ingredient in Vyleesi®, an FDA-approved medication for acquired, generalized HSDD in certain premenopausal women. Compounded PT-141 is a different product. It is not FDA-approved, and the clinical trials that supported Vyleesi®’s approval did not study it. We can’t say what compounded PT-141 will do for you. A licensed provider can discuss whether it’s appropriate and whether an FDA-approved option is a better fit.
Bremelanotide is the active ingredient in Vyleesi®, an FDA-approved prescription medication administered by subcutaneous injection.
Vyleesi® is indicated for premenopausal women with acquired, generalized HSDD when low sexual desire causes significant distress or interpersonal difficulty and is not primarily explained by another medical or psychiatric condition, relationship problems, or medication effects.
The FDA-approved product is not indicated for:
Compounded PT-141 may be prescribed in certain circumstances by a licensed healthcare provider. However, compounded medications are not FDA-approved and have not undergone FDA review for safety, effectiveness, and quality before marketing in the same way as approved medications.
PT-141 is available through independent licensed providers on the platform. A licensed healthcare provider must determine whether treatment is appropriate for the individual patient. There are no FDA-approved PT-141 products for men. Vyleesi® is FDA-approved bremelanotide for premenopausal women. The compounded PT-141 is prepared by licensed U.S. compounding pharmacies for individual patients.
Bremelanotide may slow gastric emptying and affect the absorption of certain oral medications. It may also reduce the effectiveness of oral naltrexone, which is used in some patients for alcohol or opioid use disorders. This list is not exhaustive. A licensed healthcare provider should carefully review medical history, medications, and individual risk factors before prescribing a compounded PT-141 formulation.
PT-141 can cause side effects, and the FDA-approved bremelanotide product has specific safety warnings.
Nausea is particularly common. In clinical trials of Vyleesi®, approximately 40% of treated patients reported nausea. Some required medication to manage it, and nausea led some participants to discontinue treatment.
Cash-pay only, with no insurance claims. Payment does not guarantee a prescription. Your card is authorized at checkout and charged only if a licensed provider prescribes. If nothing is prescribed, the hold is released.
Billed per your chosen plan until you cancel. Every plan includes:
Cancel anytime by selecting “Cancel Subscription” in your patient portal, at least 48 hours before your next billing date. If a charge goes through after a successful cancellation, it will be refunded. See the Cancellation & Refund Policy.
PT-141, or bremelanotide, is a synthetic peptide that activates melanocortin receptors involved in neurological pathways associated with sexual desire and response. It works differently from medications such as Viagra, which primarily improve blood flow.
Compounded PT-141 is not FDA-approved for any use. A licensed provider can evaluate your concerns and discuss your options.
Compounded PT-141 is not FDA-approved for any use. A licensed provider can evaluate your concerns and discuss your options.
Compounded PT-141 is not FDA-approved for any use. A licensed provider can evaluate your concerns and discuss your options.
Bremelanotide is FDA-approved as Vyleesi® for acquired, generalized HSDD in premenopausal women. It is not approved for men, postmenopausal women, or general sexual performance enhancement. Compounded PT-141 is not FDA-approved. Compounded products are not reviewed by the FDA for safety, effectiveness, and quality before marketing in the same way as FDA-approved medications. PT-141 is available through independent licensed providers on the platform. It is prepared by licensed U.S. compounding pharmacies for individual patients.
The most common side effects include nausea, flushing, headache, vomiting, and injection-site reactions. Bremelanotide can also temporarily increase blood pressure and decrease heart rate. Skin hyperpigmentation has been reported.
Yes. Bremelanotide can cause a temporary increase in blood pressure and a decrease in heart rate. It is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease under the FDA-approved Vyleesi® labeling.
No. PT-141 is a synthetic peptide that acts on melanocortin receptors. It is not estrogen or another sex hormone. Its effects are related to neurological signaling pathways involved in sexual desire and response.
More in the full FAQ.
A short online consultation, reviewed by a licensed provider. If it's not a fit, they'll tell you.
PT-141 is a compounded medication. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, and quality before marketing in the same way as an approved drug. The FDA-approved product Vyleesi® is indicated only for premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is not indicated for men, postmenopausal women, or general sexual performance enhancement. PT-141 requires a prescription from a licensed provider, who decides whether it is appropriate for you. Payment does not guarantee a prescription. Care is provided by independent licensed providers of the medical group assigned to you. Individual results vary. This page is educational and is not medical advice. Vyleesi® is a registered trademark of Cosette Pharmaceuticals, Inc. Viagra® is a registered trademark of Viatris Specialty LLC. Jellyphysh is not affiliated with or endorsed by these companies. Content last reviewed: [date] by [reviewer, credentials].